• Market Capitalisation market-capitalisation-info $470 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-409 Mln

Calliditas Therapeutics AB (CALT) Share Price

$18.78

As on 28-Nov-2023 14:31 EST

up-down-arrow $-0.19-1.00%

  • Prev Close info

    $18.97

  • Day's Openinfo

    $18.46

  • Today's Highinfo

    $18.95

  • Today's Lowinfo

    $18.40

  • Today's Volumeinfo

    8,103

  • 52 Week rangeinfo

    $15.25 - 25.64

Please wait...

Calliditas Therapeutics AB (CALT) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Calliditas Therapeutics AB (CALT)
10.47 16.57 5.51 9.12 -17.27 -- --
S&P BSE Sensex*
10.91 5.65 4.09 6.94 15.19 13.27 12.49
#
-- -- -- -- -- -- --
As on 28-Nov-2023  |  *As on 01-Dec-2023  |  #As on
2022
2021
Calliditas Therapeutics AB (CALT)
-31.34 -26.35
S&P BSE Sensex
4.44 21.99
S&P BSE Sensex
4.44 21.99

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Calliditas Therapeutics AB (CALT) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Calliditas Therapeutics AB (CALT)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Calliditas Therapeutics AB (CALT)

        Chief Exec. Officer

        Ms. Renee Aguiar-Lucander

        Chief Financial Officer

        Mr. Fredrik Johansson

        Headquarters

        Stockholm

        FAQs for Calliditas Therapeutics AB (CALT)

        The total asset value of Calliditas Therapeutics AB (CALT) stood at $ 1,953 Mln as on 31-Dec-22

        The share price of Calliditas Therapeutics AB (CALT) is $18.78 (NASDAQ) as of 28-Nov-2023 14:31 EST. Calliditas Therapeutics AB (CALT) has given a return of -17.27% in the last 3 years.

        Calliditas Therapeutics AB (CALT) has a market capitalisation of $ 470 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Calliditas Therapeutics AB (CALT) is 7.39 times as on 02-Jun-2023, a 1.91% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Calliditas Therapeutics AB (CALT) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Calliditas Therapeutics AB (CALT) and enter the required number of quantities and click on buy to purchase the shares of Calliditas Therapeutics AB (CALT).

        Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.

        The CEO & director of Ms. Renee Aguiar-Lucander. is Calliditas Therapeutics AB (CALT), and CFO & Sr. VP is Mr. Fredrik Johansson.

        The promoters of Calliditas Therapeutics AB (CALT) have pledged 0% of the total equity as on Mar-23.

        Some of the close peers are:

        Company Market Cap($ Mln)
        Calliditas Therapeutics AB (CALT) Ratios
        Return on equity(%)
        -46.46
        Return on capital employed(%)
        -30.35
        Debt-to-equity ratio
        0.95
        Dividend yield(%)
        --

        No, TTM profit after tax of Calliditas Therapeutics AB (CALT) was $-409 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $470.17 Mln
        • Revenue (TTM)revenue-information kr802.88 Mln
        • Earnings (TTM) earning-information kr-408.59 Mln
        • Cash date-information kr1,249.09 Mln
        • Total Debt info kr728.82 Mln
        • Insider's Holding 0.00%
        • Liquidity liquidity High
        • 52 Week range week-range $15.25 - 25.64
        • Shares outstanding share-outstanding 26,836,000
        • 8 Years Aggregate:

          CFO: kr-1,453.68 Mln

          EBITDA: kr-1,673.55 Mln

          Net Profit: kr-1,717.66 Mln

        About The Company

        • IPO Date 05-Jun-2020
        • Chief Exec. Officer Ms. Renee Aguiar-Lucander
        • Chief Financial Officer Mr. Fredrik Johansson
        • Listing key-listing NASDAQ: CALT
        • Country Sweden
        • Headquarters headquarters Stockholm
        • Website website https://www.calliditas.se
        • Business

          Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic...  diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon